Overview
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
Eligibility
Inclusion Criteria:
- Written informed consent from parents/care givers and patient assent if age appropriate
- Initiation of Pradaxa Pellets administration either as initial or subsequent therapy:
- Treatment of venous thromboembolic events (VTE)
- Treatment to reduce the risk of recurrence of VTE
Exclusion Criteria:
- Participation in any randomized clinical trial or use of investigational product, participation in any other observational study is not an exclusion
- Any contraindications to Pradaxa Pellets according to the US Prescribing Information.
- Previous participation in this study.
